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ABSTRACT 
Helical tomotherapy is a new form of image-guided radiation therapy that combines features of a linear accelerator 
and a helical computed tomography (CT) scanner. Megavoltage CT (MVCT) data allow the verification and correction 
of patient setup on the couch by comparison and image registration with the kilovoltage CT multi-slice images used for 
treatment planning. An 84-year-old male patient with Stage III bulky non-small cell lung cancer was treated on a Hi-
ART II tomotherapy unit. Daily MVCT imaging was useful for setup corrections and signaled the need to adapt the 
delivery plan when the patient’s anatomy changed significantly. © 2007 Biomedical Imaging and Intervention Journal. 
All rights reserved. 
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INTRODUCTION 
Helical tomotherapy is a radiotherapy technique that 
combines the geometry of a diagnostic helical Computed 
Tomography (CT) scanner with the capability to deliver 
highly conformal radiation dose distributions in an 
intensity-modulated fashion [1,2]. The same linac is also 
used for obtaining MVCT images prior to actual daily 
fractionated treatment. There are at least two major 
benefits provided by such imaging: i) a correction of 
setup errors [3-5] which is especially important in cases 
where rigid immobilisation is difficult or internal motion 
is common (i.e. extracranial sites such as 
thorax/abdomen, some lung cancer patients have 
difficulty in keeping their arms up even in a vac-loc 
immobilisation device, mostly because of arthritis in the 
shoulders) and ii) a modification of the treatment itself 
based on information obtained from MVCT images. The 
latter feature, often referred to as image-guided adaptive 
radiotherapy, has already been discussed in the literature 
[6-10]. Ramsey et al. have done a retrospective treatment 
planning study and concluded that weekly plan 
adjustment of tomotherapy plans may reduce the 
absolute volume of ipsilateral lung receiving 20 Gy by 
17-23% in lung cancer patients [6,10]. Kupelian et al. 
have observed a gradual reduction of the gross tumour 
volume (GTV) ranging from 0.6-2.3% per day in their 
non-small-sell lung cancer patients treated on the 
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tomotherapy unit [7-9]. In this communication, we 
describe a clinical case where treatment plan was 
modified after 22 fractions and various options to 
perform adaptive radiotherapy were discussed based on 
information provided by a daily MVCT imaging. In 
particular, we assess the clinical significance of 
modifications made to radiation delivery plans prompted 
by changes in GTV revealed by MVCT images during 
fractionated lung cancer treatment on the tomotherapy 
unit. 
METHODS AND MATERIALS 
An 84-year-old male patient presented with 
symptomatic left upper lobe and hilar mass, Stage III 
bulky non-small cell lung cancer without atelectasis. A 
kilovoltage CT (kVCT, Philips Brilliance Big Bore, 3 
mm slice thickness, 120 kVp, 300 mAs/Slice) image 
(Figure 1) was taken 17 days before the start of treatment 
and the radiation oncologist (ARD) outlined two targets 
(gross tumour volume (GTV) and mediastinal nodes) and 
the following sensitive structures: lungs, esophagus, 
spinal cord, heart. Planning target volumes (PTV) were 
created by a 12 mm 3D margin around GTV (PTV Lung) 
and around mediastinal nodes (PTV Nodes). Doses of 60 
Gy to PTV Lung and 50 Gy to PTV Nodes in 30 
fractions were prescribed. The helical tomotherapy plan 
based on this anatomy (plan 1: field slice thickness 2.5 
cm, pitch 0.286, expected beam-on time 465 s per 
fraction) was approved for treatment. All treatments 
were preceded by daily MVCT imaging (Figure 2). The 
MVCT study was used for two reasons: a) to correct for 
inter-fraction changes of the patient’s position (Figure 3) 
on the couch by co-registration of the MVCT study with 
the kVCT study used for treatment (Figure 4), and b) to 
assess variations in tumour size and/or positioning inside 
the patient. MVCT images for all treatment days were 
transferred to the planning station and GTV were 
contoured on all of them. The variation of the GTV with 
time is presented in Figure 5. The error bars were 
determined by outlining the maximum and minimum 
imaginable GTVs on MVCT studies made on Day 1 and 
Day 43 of treatment. After 15 fractions, the MVCT 
images showed a tumour size reduction of 70%. 
However, the radiation oncologist decided to continue 
the treatment according to Plan 1 until delivery of 44 Gy 
in 22 fractions to ensure sterilisation of a sub-clinical 
microscopic disease of the initial target. A repeat kVCT 
study (Figure 6) was performed and a new plan with new 
structure outlines to reflect the anatomy changes (Plan 2: 
beam-on time 388 s) was applied for the remaining eight 
fractions. To test the clinical significance of the margin 
choice we have created another set of target outlines 
(Figure 7) with a 0.5 cm margin around GTVs. 
Subsequent follow-ups after four and eight months 
showed (by physical examination and diagnostic kVCT 
with contrast) moderate radiation pneumonitis (Grade 2) 
that resolved with fibrosis. The patient follow up 
continued for 11 months with no evidence of cancer 
recurrence. 
RESULTS AND DISCUSSION 
Sensitive structures tolerance dose criteria [11] were 
met in all three plans as shown in the dose-volume 
histograms (DVH) for plans 1, 2, and 3 in Figures 8 (a), 
(b), and (c), respectively. The full dose was delivered to 
the primary target and the nodes without any side effects. 
The PTV was reduced to 769 cm
3 in Plan 1 to 386 cm
3 in 
Plan 2 and to 193 cm
3 in Plan 3. The calculated mean 
lung dose was 16.3 Gy according to Plan 1, 10.4 Gy in 
Plan 2, and 7.9 Gy in Plan 3. The planned dose 
distribution according to Plan 1 is shown in Figure 9. We 
note high conformity of the 60 Gy isodose line to the 
PTV contour. If this plan would have been delivered 39 
days after the start of the treatment when the tumour size 
has been significantly reduced (Figure 5), a large region 
of healthy lung tissue would have been irradiated as 
shown in Figure 10. However, Plan 2 (adapted for the 
changing tumour size) delivers the prescription dose 
quite comfortably on Day 39 (Figure 11), with no 
Figure 1  Axial slice of kVCT study made 17 days before 
treatment start date. This was used for the creation of 
treatment Plan 1. 
 
 
Figure 3  Daily setup shifts determined from MVCT/kVCT 
registration. 
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Figure 2  30 images corresponding to 30 fractions of treatment. Reduction of tumour volume is clearly observed. 
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Figure 4  Registration screen on the operating station used for automatic and/or manual alignment of the MVCT 
images (upper left and green colour on the central frame) with the planning kVCT images (lower left 
and white colour on the central frame). 
 
 
 
 
Figure 5  GTV reduction during the treatment showing three distinct phases. 
 
 
 
   
Figure 6  Axial slice of kVCT study made 39 days after treatment 
start date. This study, with the 3D margin around GVT of 
1.2 cm was used for the creation of treatment Plan 2. 
Figure 7  Axial slice of kVCT study made 39 days after treatment 
start date. This study with the 3D margin around GVT of 
0.5 cm was used for the creation of treatment Plan 3. 
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(a) 
 
(b) 
 
(c) 
Figure 8  (a) Dose volume histogram of Plan 1. Colour code: black: GTV; red: PTV; violet: PTV Nodes; blue: left 
lung; light blue: right lung; yellow: spinal cord; brown: oesophagus, (b) dose volume histogram of Plan 
2, (c) dose volume histogram of Plan 3. 
 
 
 
 
 
 
 
 
(a) 
 
(b) 
 
(c) 
Figure 9  Dose distribution ((a) axial and (b) sagittal views) as calculated by Plan 1 on the kVCT image used for 
this plan. (c) Colour code for isodose lines. 
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(a) 
 
(b) 
 
(c) 
Figure 10 Dose distribution ((a) axial and (b) sagittal views) which would have been produced by radiation fluence 
of Plan 1 in the patient on 39th day of the treatment. (c) Colour code for isodose lines. 
 
 
 
(a) 
 
(b) 
 
(c) 
Figure 11 Dose distribution ((a) axial and (b) sagittal views) produced by radiation fluence of Plan 2 in the patient 
on 39th day of treatment. (c) Colour code for isodose lines. 
 
 
 
 
(a) 
 
(b) 
 
(c) 
Figure 12 Dose distribution ((a) axial and (b) sagittal views) which would have been produced in the patient on 
39th day of treatment if radiation fluence of Plan 3 is used. (c) Colour code for isodose lines. 
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irradiation to healthy lung tissue due to a lower mean 
lung dose of 10.4 Gy. Clinically, there is a possibility to 
reduce the margin around GTV after delivery of 44 Gy 
because the microscopic disease spread which defines 
the margin of PTV to CTV should be eliminated by this 
dose. In this case, we can use quite a tight margin for 
generating the PTV, because set-up errors are under 
control by the registration process shown in Figure 4. 
Our calculations with the plan with such a tighter margin 
(Plan 3) gave a dose distribution presented in Figure 12 
with superior lung tissue sparing and a mean lung dose 
of only 7.9 Gy.  
In this case, there were at least three phases in 
tumour reduction, with initial phase of ca. 10 fractions 
(or 20 Gy with delivery of 2 Gy per fraction) when 
tumour reduction of 1.6% per day was noted. After this 
dose there was a rather rapid reduction in tumour size, of 
more than 5% per day which continued for three weeks 
until 40 Gy was administered. Finally, there was a slow 
reduction in tumour volume at 0.5% per day which 
probably continued when the treatment was finished at 
60 Gy. The possible mechanisms for such a three phase 
reduction include an initial accumulation of radiation 
damage in Phase 1 before a radiosensitive Phase 2 of 
rapid reduction due to re-oxygenation occurs, while in 
Phase 3 cell death is counterbalanced by repopulation. 
Such a hypothesis requires verification in larger number 
of patients and correlation with histology or non-invasive 
information about tumour metabolism by PET/SPECT. 
CONCLUSION 
The combined usage of kVCT and MVCT studies 
allowed high quality kVCT images for precise radiation 
dose calculations on tomotherapy planning station for 
both initial and adapted plans, while MVCT scans were 
used for accurate patient setup and monitoring of tumour 
evolution. MVCT has sufficient image quality for 
verification of daily treatment delivery allowing for plan 
adaptation according to tumour response. It can be used 
to quantitatively measure tumour response during 
radiotherapy. Furthermore, daily imaging provides data 
necessary for an optimal choice of GTV to PTV margin 
based on values for setup corrections and tumour 
dynamics. 
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